This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
9 Jan 2019

Expedeon signs supply and license agreement for is Lightning-Link technology

Dr Heikki Lanckriet, CEO and CSO of Expedeon.

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Expedeon has signed a supply and license agreement with Cell Guidance Systems, a developer of therapeutic products for medicine and life science research, for use of Expedeon’s proprietary Lightning-Link Rapid Biotin technology in the development and production of TRIFic (Time Resolved Immunofluorescence Exosome Detection Assay) immunoassays. Cell Guidance Systems has already benefitted from the application of Expedeon’s Lightning-Link technology for more than 2 years, and under this new agreement Expedeon becomes preferred immunoreagent supplier to the company

Cell Guidance Systems’ TRIFic rapid detection assay provides quantitative data from purified and unpurified samples, including direct measurements of exosomes in plasma. TRIFic exosome assays are available for widely used markers of exosomes, including the tetraspanin proteins CD9, CD63 and CD81, and provides high sensitivity detection levels which are clear and consistent over a wide range of samples.

The Expedeon Lightning-Link Rapid Biotin kit enables the rapid, direct biotinylation of antibodies, proteins and peptides, or any other biomolecule with an available amine group, with 100% recovery of materials. The kit is optimized for assays in which the biotinylated protein is captured by streptavidin immobilized on a surface. The kit requires only 30 seconds hands-on time and the conjugates are ready to use in under 20 minutes. The technology is fully scalable from 10 ug to 1 g or over, and is stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.

Using Expedeon’s Lightning-Link biotin technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results. Cell Guidance Systems will benefit from cost savings on detection antibodies and secondary immunoreagents, plus improved production yields and enhanced quality of immunoassay handling.

Dr Heikki Lanckriet, CEO and CSO of Expedeon, commented: “We have been working with Cell Guidance Systems for several years and are delighted to strengthen the relationship. Our technology provides a rapid, easy to use, efficient method of labelling antibodies and we are confident it will serve Cell Guidance Systems very well in the development and production of their TRIFic detection assay kits. This latest agreement follows a number of license and supply agreements with various partners for Lightning-Link, underlining the increasing demand in academia and industry for our proprietary solutions, which help drive the life sciences research sector.”

Dr Laur-Alexandru Botos, Senior Research Scientist at Cell Guidance Systems said: “TRIFic kit is an exquisitely sensitive europium time resolved immunofluorescence assay for exosome markers. The Lightning-Link® Rapid Biotin technology is used to generate stable biotin conjugates as components of this platform. We have found Expedeon’s cutting edge technologies to be reliable and meet the high standards that our customers demand, and will be invaluable in ensuring the TRIFic detection assay kits enable researcher to save time and costs.”

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.